Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer

Sha, Shengnan; Si, Luyi; Wu, Xinrui; Chen, Yuanbiao; Xiong, Hui; Xu, Ying; Liu, Wangrui; Mei, Haijun; Wang, Tao; Li, Mei

doi:10.3389/fimmu.2022.922780

Cited by 84 publications

(69 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies have applied CRGs to predict outcomes and guide treatments for cancer patients, for example, triple-negative breast cancer, hepatocellular carcinoma, and bladder cancer patients. As shown in previous studies, CRGs are closely related to the prognosis of breast cancer patients (Sha et al, 2022). In addition, the cuproptosis-related risk score could divide liver cancer patients into two groups with differences in mutation status and responded to target therapy in different ways (Zhang et al, 2022).…”

Section: Discussionmentioning

confidence: 80%

Cuproptosis-related gene signature stratifies lower-grade glioma patients and predicts immune characteristics

Zhang

Wang²,

Xu³

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Cuproptosis is the most recently discovered type of regulated cell death and is mediated by copper ions. Studies show that cuproptosis plays a significant role in cancer development and progression. Lower-grade gliomas (LGGs) are slow-growing brain tumors. The majority of LGGs progress to high-grade glioma, which makes it difficult to predict the prognosis. However, the prognostic value of cuproptosis-related genes (CRGs) in LGG needs to be further explored. mRNA expression profiles and clinical data of LGG patients were collected from public sources for this study. Univariate Cox regression analysis and the least absolute shrinkage and selection operator (LASSO) Cox regression model were used to build a multigene signature that could divide patients into different risk groups. The differences in clinical pathological characteristics, immune infiltration characteristics, and mutation status were evaluated in risk subgroups. In addition, drug sensitivity and immune checkpoint scores were estimated in risk subgroups to provide LGG patients with precision medication. We found that all CRGs were differentially expressed in LGG and normal tissues. Patients were divided into high- and low-risk groups based on the risk score of the CRG signature. Patients in the high-risk group had a considerably lower overall survival rate than those in the low-risk group. According to functional analysis, pathways related to the immune system were enriched, and the immune state differed across the two risk groups. Immune characteristic analysis showed that the immune cell proportion and immune scores were different in the different groups. High-risk group was characterized by low sensitivity to chemotherapy but high sensitivity to immune checkpoint inhibitors. The current study revealed that the novel CRG signature was related to the prognosis, clinicopathological features, immune characteristics, and treatment perference of LGG.

show abstract

Section: Discussionmentioning

confidence: 80%

Cuproptosis-related gene signature stratifies lower-grade glioma patients and predicts immune characteristics

Zhang

Wang²,

Xu³

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…The cuproptosis-related risk profiles for lncRNA may aid in determining the prognosis and molecular profile of patients with ccRCC, lung adenocarcinoma, and hepatocellular carcinoma as well as improving therapy choices that may be used in the clinic [40][41][42]. According to the current study, a novel signature based on the cuproptosis gene may be able to predict a patient's prognosis, biological makeup, and the best course of therapy for them if they have glioma or triple negative breast cancer [43,44]. The immune microenvironment and tumor immunotherapy may both be affected by cuproptosis-related lncRNAs at the same time [45][46][47].…”

Section: Discussionmentioning

confidence: 89%

Identification and validation of a novel cuproptosis-related lncRNA gene signature to predict prognosis and immune response in bladder cancer

Chen

Guan

et al. 2022

Discov Onc

View full text Add to dashboard Cite

Purpose Bladder cancer (BCa) is one of the most common malignant tumors in the urogenital system, characterized by the high recurrence rate, mortality rate and poor prognosis. Based on cuproptosis-related long noncoding RNAs (CRLs), this study set out to create a prediction signature to evaluate the prognosis of patients with BCa. Methods RNA-seq data including CRLs and related clinicopathological data were gathered from The Cancer Genome Atlas (TCGA) database (n = 428). The predictive signature was constructed after correlation analysis. Subsequently, relying on the analyzed data from the TCGA database and our sample collection, we examined and verified the connections between CRLs model and important indexes included prognosis, route and functional enrichment, tumor immune evasion, tumor mutation, and treatment sensitivity. Results Patients in the high-risk group had lower overall survival (OS) than that of low-risk group. Compared with clinicopathological variables, CRLs features have better predictive value according to receiver operating characteristic (ROC) curve. The expression level of CRLs was highly associated with the tumor progress, tumor microenvironment and tumor immune escape. Additionally, we identified that the mutation of TP53, TTN, KMT2D and MUC16 gene were founded in patients with BCa. Lapatinib, pazopanib, saracatinib, gemcitabine, paclitaxel and palenolactone had good antitumor effects for BCa patients in the high-risk group (all P < 0.001). Conclusion This study revealed the effects of CRLs on BCa and further established CRLs model, which can be used in clinic for predicting prognosis, immunological response and treatment sensitivity inpatient with BCa.

show abstract

“…In this work, we rst implemented the functional enrichment of 10 cuproptosis genes in BRCA. We found that most of these genes are involved in biological processes 'acetyl-CoA biosynthetic process from pyruvate', 'mitochondrial acetyl-CoA biosynthetic process from pyruvate' and 'tricarboxylic acid cycle', which are all closely linked to the development of BRCA (23). We discovered that of the 10 cuproptosis genes, CDKN2A and PDHB expression were dramatically increased in BRCA samples as compared to normal samples, but the expression of the other genes was signi cantly decreased.…”

Section: Discussionmentioning

confidence: 91%

Bioinformatic analysis and experimental validation of six cuproptosis-associated genes as prognostic signatures in breast cancer

Chen

Sun

Yang

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Breast carcinoma (BRCA) is the life-threatening malignancy in women with poor prognosis. Cuproptosis is a novel mode of cell death, and its relationship with BRCA is unclear. This study endeavored to develop the cuproptosis-relevant prognostic genes and signature for BRCA. Methods Cuproptosis-relevant subtypes of BRCA patients were derived by consistent clustering. Disparate expression analysis was implemented in the ‘limma’ package. The univariate Cox and multivariate Cox analysis were executed to determine the cuproptosis-relevant prognostic signature. The signature was created and affirmed in distinct datasets. The Gene Set Variation Analysis (GSVA) and Gene Set Enrichment Analysis (GSEA) were also conducted to uncover the molecular mechanisms involved in the prognostic signature. ESTIMATE and CIBERSORT algorithm were applied to probe the linkage between the gene signature and tumor microenviroment (TME). Immunotherapy responsiveness were projected by Tumor Immune Dysfunction and Exclusion (TIDE) website. Detection of the expression of cuproptosis-revelant prognostic genes in breast cancer cell lines was implemented by Real Time Quantitative PCR (RT-qPCR). Results A grand total of 38 cuproptosis-associated differentially expressed genes (DEGs) in BRCA were mined by consistent clustering and disparate expression analysis. Based on univariate Cox and multivariate Cox analysis, six cuproptosis-revelant prognostic genes, namely SAA1, KRT17, VAV3, IGHG1, TFF1 and CLEC3A, were mined to establish a cuproptosis-revelant signature. Then, we affirmed the signature by external validation set. GSVA and GSEA manifested that multiple cell cycle-linked and immune-related pathways and biological processes were connected to the signature. The ESTIMATE and CIBERSORT results revealed significantly different TMEs for the two Cusig score subgroups. Finally, the result of RT-qPCR of cell lines further affirmed the expression trend of SAA1, KRT17, IGHG1 and CLEC3A. Conclusion Taken together, this study authenticated the cuproptosis-revelant prognostic genes and developed a signature for the overall survival projection of BRCA, which will provide the basis for developing prognostic molecular biomarkers and in-depth understanding of the relationship between cuproptosis and BRCA.

show abstract

Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer

Cited by 84 publications

References 62 publications

Cuproptosis-related gene signature stratifies lower-grade glioma patients and predicts immune characteristics

Cuproptosis-related gene signature stratifies lower-grade glioma patients and predicts immune characteristics

Identification and validation of a novel cuproptosis-related lncRNA gene signature to predict prognosis and immune response in bladder cancer

Bioinformatic analysis and experimental validation of six cuproptosis-associated genes as prognostic signatures in breast cancer

Contact Info

Product

Resources

About